The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

NEW HAVEN, CT, USA I5, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the ...

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...

SÖDERTÄLJE, Sweden I6, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the ...

– Interim results indicate cognitive improvement in the active treatment group compared to placebo ...

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S.

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and ...

WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...